|
May 14
|
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
|
May 14
|
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
|
May 14
|
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine P...
|
|
May 14
|
SCLX Grows Revenue and Expands Portfolio
|
|
May 13
|
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
|
|
Apr 25
|
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
|
|
Apr 24
|
Scilex Holding Company Announces $15 Million Registered Direct Offering
|
|
Apr 16
|
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other...
|
|
Apr 9
|
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
|
|
Mar 27
|
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
|
|
Mar 21
|
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
|
|
Mar 20
|
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
|
|
Mar 20
|
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colch...
|
|
Mar 19
|
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
|
|
Mar 18
|
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura ...
|
|
Mar 15
|
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
|
|
Mar 15
|
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of...
|
|
Mar 14
|
Scilex Holding Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 12
|
SCLX Grows Revenue and Boosts Marketing
|
|
Mar 9
|
Scilex Holding Company (NASDAQ:SCLX) most popular amongst private companies who own 57% of the shares, institutions hold 25%
|